NaviMed Capital Closes Fund III at $450 Million Hard Cap

– NaviMed Capital, a Washington, DC-based private equity firm, has closed its third fund, NaviMed Partners III (“Fund III”), at a hard cap of $450 million.

– The new fund brings NaviMed’s total capital commitments to over $850 million.

– The firm focuses on control investments in fast-growing lower middle-market healthcare companies.

– Specializes in acquiring businesses that provide business process outsourcing services to healthcare providers, insurers, and the pharmaceutical and medical device industries.

– NaviMed targets profitable private companies with up to $10 million of EBITDA and double-digit annual revenue growth.

– Fund III has been oversubscribed, supported by investors including endowments, foundations, insurance companies, pensions, financial institutions, and family offices.

– Ryan Schwarz, co-founder and Managing Director, stated: “NaviMed will continue to execute our proven ‘Thesis-Driven, Executive-Led’ strategy in Fund III. We seek to partner with business owners to build upon the foundations they have created.”

– Dr. Bijan Salehizadeh, co-founder and Managing Director, added: “We are grateful for the support from our new and returning investors, which include endowments, foundations, insurance companies, financial institutions, and family offices.”

– Since mid-2021, NaviMed has sold or recapitalized six portfolio companies, including Argos Health, CenterPointe Behavioral Health System, The CM Group, Lighthouse Lab Services, Lucent Health, and Velocity Clinical Research.

– The firm follows a “Thesis-Driven, Executive-Led” strategy, partnering with business owners to drive growth through human capital, regulatory insights, and funding for acquisitions.

– NaviMed’s investment team is supported by a group of Senior Advisors and Health Policy Partners with expertise in healthcare policy.

– Legal advisor: Ropes & Gray LLP; Financial advisor and placement agent: Metric Point Capital.